XL557 / Exelixis - LARVOL DELTA

Anticipated R&D Milestones:…Two Potential IND Applications in 2026 (Businesswire) - "Exelixis anticipates advancing two programs into clinical development this year: (i) XL557 is an orally bioavailable small molecule Somatostatin Receptor 2 agonist. Somatostatin analogs are widely used in the first- and second-line NET treatment settings....; (ii) XB773 is an antibody-drug conjugate (ADC) consisting of an exatecan payload conjugated to a monoclonal antibody targeting DLL3, a transmembrane protein that is expressed in neuroendocrine carcinomas such as small cell lung cancer and neuroendocrine prostate cancer."

IND • Neuroendocrine Carcinoma • Prostate Cancer • Small Cell Lung Cancer